Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CareDx (CDNA – Research Report), Merit Medical Systems (MMSI – Research Report) and HealthStream (HSTM – Research Report).
CareDx (CDNA)
Craig-Hallum analyst Alexander Nowak maintained a Hold rating on CareDx today. The company’s shares closed last Tuesday at $11.01.
According to TipRanks.com, Nowak is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for CareDx.
See the top stocks recommended by analysts >>
Merit Medical Systems (MMSI)
Barrington analyst Michael Petusky maintained a Buy rating on Merit Medical Systems today and set a price target of $95.00. The company’s shares closed last Tuesday at $81.53, close to its 52-week high of $85.62.
According to TipRanks.com, Petusky is a 5-star analyst with an average return of
Currently, the analyst consensus on Merit Medical Systems is a Moderate Buy with an average price target of $90.50, representing a 13.3% upside. In a report issued on July 21, Piper Sandler also assigned a Buy rating to the stock with a $92.00 price target.
HealthStream (HSTM)
Barrington analyst Vincent Colicchio maintained a Hold rating on HealthStream today. The company’s shares closed last Tuesday at $22.88.
According to TipRanks.com, Colicchio is a 5-star analyst with an average return of
Currently, the analyst consensus on HealthStream is a Moderate Buy with an average price target of $22.00, which is a -13.2% downside from current levels. In a report released today, Canaccord Genuity also maintained a Hold rating on the stock with a $22.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CDNA:
- CareDx acquires organ transplant supply chain firm MediGO, no terms
- CareDx announces district court upholds March 2022 jury verdict against Natera
- Natera announces ruling in favor of the company in CareDx false advertising case
- CareDx reimbursement uncertainty remains, says Raymond James
- CareDx: dd-cfDNA molecular testing service receives Medicare coverage
